Alba by Quotient™ portfolio now available in additional European markets

We are pleased to announce that Alba by Quotient™ continues to grow in Europe and is now available in the Netherlands and Sweden in addition to the following geographies:

Quotient Abstract Submission Accepted at EULAR Annual Meeting

We are excited to share that our abstract titled: “Performance of a solid-phase photometric single use immunoassay microarray pr

Quotient will exhibit at ISBT Gothenburg, Sweden 2023.

We are pleased to share that we will be exhibiting at the 33rd Regional Congress of the 

ALBA receives product group certification for Class C Blood Grouping Reagents under new IVDR standards.

In May 2022, the EU implemented the new in-vitro medical devices Regulation (IVDR) to ensure the safety and performance of in-vit

Alba by Quotient™ Now Available in Germany, France, Luxembourg, Austria and Slovakia!

Alba by Quotient™ believes in creating value for laboratories, that’s why in addition to a portfolio of high-quality blood bank reagents, we also offer:

Quotient Successfully Emerges from Chapter 11 Process and Completes Refinancing Plan

•    Raised $51 million of new capital and reduced debt by approximately $140 million
•    Company to refocus commercial effort on Alba and expand MosaiQ into autoimmune and allergy 


Quotient Limited Announces Second Quarter Fiscal 2023 Business Update (10-Q)

To read the full 10-Q, please visit: 

Quotient Limited Selected to Join the World Economic Forum New Champions Community

• The World Economic Forum’s New Champions Community brings together purpose driven companies of mid-size whose leadership is mindful of their impact on society and aspiring in building a better future 


KOL Event On MosaiQ™ Solution

Quotient hosted a key opinion leader (KOL) webinar on the current landscape and unmet needs within blood grouping and donor disease screening,

Quotient Limited Announces Receipt of CE Mark for the Extended Immunohematology Microarray